Arizona Grain Incorporated v. Barkley Ag Enterprises LLC

District Court, D. Arizona·Decided April 10, 2020·No. 2:18-cv-03371·Unknown

Opinion

WO

Arizona Grain Incorporated, et al., No. CV-18-03371-PHX-GMS

Plaintiffs, ORDER

v.

Barkley Ag Enterprises LLC, et al.,

Defendants. Northern Agri Brands, LLC,

Counterclaim Plaintiff,

v.

Arizona Plant Breeders, Inc., et al.,

Counterclaim Defendants. Northern Agri Brands, LLC, Third-Party Plaintiff, v. Eric Wilkey; et al.,

Third-Party Defendants. Pending before the Court are Lockwood Seed and Grain’s Motion to Dismiss for Lack of Jurisdiction and for Failure to State a Claim, (Doc. 68); Northern Agri Brands, LLC (“NAB”)’s Motion for Leave to Supplement Opposition to Motion to Dismiss and to Seal Document Exhibits A & B in Support of Supplemental Opposition, (Doc. 81); NAB’s Motion to Amend/Correct Amended Counterclaim, Amended Third Party Complaint, (Doc. 84); and NAB’s Motion to Seal Document Declaration of Glenn Johnson and Exhibits 1-8 iso Reply re Motion for Leave to Amend, (Doc. 93).1 The Motion to Dismiss is granted in part and denied in part, the Motion for Leave to Supplement is denied, the Motion to Amend/Correct is granted, and the Motion to Seal is granted. Because the factual background of this case was summarized in the Court’s order on Lockwood’s prior motion to dismiss, the Court will not restate it here. (See Doc. 62 at 2–5.) I. NAB’s Motion for Leave to Supplement Opposition to Motion to Dismiss NAB requests leave to supplement its opposition to Lockwood’s Motion with “new and material information” from the initial production of materials by Arizona Plant Breeders (“APB”)/Arizona Grain. (Doc. 81 at 4.) In addition to two exhibits, NAB’s motion includes a four-page “Supplemental Opposition.” Local Rule of Civil Procedure 7.2 generally does not allow filings by the party opposing a motion beyond a “responsive memorandum.” NAB has not provided a compelling reason for the Court to consider this supplemental information, which was available to NAB when it filed its original Opposition to Lockwood’s Motion to Dismiss back on January 22, 2020. In response to the suggestion that “this information could have been contained in NAB’s Opposition to the Motion to Dismiss filed in January,” NAB asserts that “Attorney Scott Johnson had left the McKee firm at nearly the same time as Lockwood filed its second Motion to Dismiss.” (Doc. 91 at 2.) Nevertheless, remaining counsel filed NAB’s Opposition and did not raise this issue with the Court prior to filing the instant Motion for Leave to Supplement. Attorney Johnson’s departure—the only

1 The parties have requested oral argument. Those requests are denied because the parties have had an adequate opportunity to discuss the law and evidence and oral argument will not aid the Court’s decision. See Lake at Las Vegas Investors Group, Inc. v. Pac. Malibu Dev., 933 F.2d 724, 729 (9th Cir. 1991). rationale provided to support this Motion—is not sufficient reason to allow supplementation. The Motion is denied.

II. NAB’s Motion to Amend/Correct Amended Counterclaim, Amended Third Party Complaint NAB also moves to Amend/Correct its Amended Counterclaim/Amended Third Party Complaint to add “new factual allegations based on information recently ascertained from APB documents.” (Doc. 84 at 3.) NAB seeks to file these additional specific allegations pursuant to Federal Rule of Civil Procedure 15(a)(2) to support its claim for the Court’s exercise of personal jurisdiction over Lockwood. (Doc 84 at 3.) Lockwood argues that the proposed amendment “would be futile in attempting to demonstrate a prima facie case of personal jurisdiction” and “NAB’s proposed amended third party complaint would still be subject to dismissal under Rule 12(b)(6).” (Doc 86 at 4, 5.) Federal Rule of Civil Procedure 15 instructs the Court to “freely give leave [to amend] when justice so requires.” As Lockwood provides no procedural basis for its objection and the deadline for amending pleadings has not yet been set, NAB’s amendment is allowed and is considered in addressing Lockwood’s Motion to Dismiss. III. NAB’s Motion to Seal2 NAB filed a Motion to Seal documents attached to its Reply in its Motion for Leave to Amend/Correct. Those documents include exhibits previously designated as “HIGHLY CONFIDENTIAL – ATTORNEYS’ EYES ONLY” pursuant to the Court’s protective order, (Doc 46), and a declaration describing those exhibits in detail. As Lockwood does not contest the confidentiality of NAB’s lodged documents, the Motion to Seal is granted. However, as NAB filed these documents with its Reply rather than the original Motion, giving Lockwood no opportunity to respond, the Court did not consider the documents in addressing the underlying Motion for Leave to Amend/Correct. / / /

2 In its Response to NAB’s Motion to Seal, (Doc. 97), NAB either intentionally or unintentionally misled the Court when, in its Reply to its Motion to Amend/Correct, it described its “PVP protected SY 158” as “awnless,” (Doc. 92 at 6n.4). IV. Lockwood’s Motion to Dismiss A. Motion to Dismiss for Lack of Jurisdiction This Court previously determined that specific personal jurisdiction3 over Lockwood was appropriate in this case. (Doc. 62.) Lockwood filed the instant Motion because it believes “the Court’s decision appears to have relied, at least in significant part, on a misapprehension of fact regarding NAB’s state of domicile” when, in distinguishing Bristol-Myers Squibb Co. v. Superior Court of California, San Francisco County, 137 S. Ct. 1773 (2017), “the Court stated ‘[u]nlike NAB, however, the plaintiffs in Bristol-Myers were not domiciled in the state where the action was brought.’” (Doc. 68 at 1, 6.) The Court was mistaken in suggesting that NAB is domiciled in Arizona. However, Bristol-Myers remains distinguishable from the instant case in several respects. First, the defendant in Bristol-Myers “did not develop Plavix [(the drug that allegedly caused the plaintiffs’ harm)] in California [(the disputed jurisdiction)], did not create a marketing strategy for Plavix in California, and did not manufacture, label, package, or work on the regulatory approval of the product in California.” Bristol-Myers, 137 S. Ct. at 1778. By contrast, NAB alleges that Lockwood’s growth and distribution of its protected triticale variety was made possible because Lockwood contracted with APB, whose research operations are primarily based in Arizona. NAB also alleges that Lockwood sold the protected triticale back to Arizona-based Arizona Grain,4 and that Lockwood directed APB/Arizona Grain to engage in breeding operations to advance the development of four genotypes of triticale, some of which contained the legally protected germplasm of NAB, in whole or part in Arizona. Second, the nonresident plaintiffs in Bristol-Myers did not allege that they obtained Plavix through California physicians or from any other California

Free access — add to your briefcase to read the full text and ask questions with AI

Arizona Grain Incorporated v. Barkley Ag Enterprises LLC, (D. Ariz. 2020).

Arizona Grain Incorporated v. Barkley Ag Enterprises LLC (Arizona Grain Incorporated v. Barkley Ag Enterprises LLC) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Conley v. Gibson
355 U.S. 41 (Supreme Court, 1957)
Dastar Corp. v. Twentieth Century Fox Film Corp.
539 U.S. 23 (Supreme Court, 2003)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Delgado v. Plaza Las Americas, Inc.
139 F.3d 1 (First Circuit, 1998)
Syngenta Seeds, Inc. v. Delta Cotton Co-Operative, Inc.
457 F.3d 1269 (Federal Circuit, 2006)
Clemens v. DaimlerChrysler Corp.
534 F.3d 1017 (Ninth Circuit, 2008)
Smith v. Jackson
84 F.3d 1213 (Ninth Circuit, 1996)
Unisource Worldwide, Inc. v. Swope
964 F. Supp. 2d 1050 (D. Arizona, 2013)
Wells Fargo & Co. v. Wells Fargo Express Co.
556 F.2d 406 (Ninth Circuit, 1977)